An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19, has caused an ongoing worldwide pandemic. Due to the rapid emergence of variants of concern (VOCs), novel vaccines and vaccination strategies are urgently needed. We developed an intranasal vaccine c...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Li, Zhang, Haiwei, Li, Moxuan, Wu, Bihao, Zhang, Zhe, Gong, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708728/
https://www.ncbi.nlm.nih.gov/pubmed/36466882
http://dx.doi.org/10.3389/fimmu.2022.1005321

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708728/
https://www.ncbi.nlm.nih.gov/pubmed/36466882
http://dx.doi.org/10.3389/fimmu.2022.1005321

Ejemplares similares